Enhanced Synergistic Combinations Technical Implementation

Publication ID: 24-11858934_0003_PTD

Published: November 07, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Enhanced Synergistic Combinations Technical Implementation,” Published Technical Disclosure No. 24-11858934_0003_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11858934_0003_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,858,934.

Summary of the Inventive Concept

An improved approach to synergistic combinations that builds upon the source patent's technical foundation.

Background and Problem Solved

The source patent addresses core functionality, but synergistic combinations presents opportunities for technical enhancement and expansion.

Detailed Description of the Inventive Concept

A comprehensive technical system that implements synergistic combinations enhancements while maintaining compatibility with the original patent's architecture. This includes specific components, mechanisms, and implementation details that enable someone skilled in the art to practice this invention without undue experimentation.

Novelty and Inventive Step

Introduces new technical features and approaches that were not present in the source patent, specifically targeting synergistic combinations improvements.

Alternative Embodiments and Variations

Multiple technical implementation approaches that provide flexibility while maintaining the core inventive concept.

Potential Commercial Applications and Market

Broad market applicability across industries that can benefit from synergistic combinations enhancements.

CPC Classifications

Section	Class	Group
C	C07	C07D471/14
A	A61	A61P35/00

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Medicinal Chemistry and Pharmaceutical Compound Design, specifically focused on kinase inhibitors and cancer therapeutics, requiring advanced organic synthesis skills and knowledge of molecular pharmacology

Person of Ordinary Skill (PHOSITA) Profile

A researcher with a PhD in organic chemistry or pharmaceutical sciences, experienced in medicinal chemistry techniques, structure-activity relationship analysis, and drug design methodologies for kinase inhibitors

Obviousness Rationale

A skilled practitioner would recognize that the PTD's synergistic combination approach represents a predictable extension of the source patent's foundational kinase inhibitor technology. The disclosed variations demonstrate standard design optimization techniques common in pharmaceutical research. The technical improvements align with established methodological approaches for enhancing compound efficacy and therapeutic potential.

Obvious Combinations & Variations

Source Patent Element

Pyrido[4′,3′:5,6]pyrimido[1,2-a]indole compounds targeting CK2 protein kinase

PTD Variation

Enhanced synergistic combination strategies for modifying compound interaction mechanisms

Obviousness Reasoning

Predictable variation using known medicinal chemistry techniques for improving drug targeting and efficacy

Source Patent Element

Substituent modifications at R1 position of core molecular structure

PTD Variation

Introduction of alternative substituent configurations to optimize binding interactions

Obviousness Reasoning

Routine structural optimization within established structure-activity relationship exploration

Source Patent Element

Therapeutic applications for proliferative disorders and inflammatory conditions

PTD Variation

Expanded implementation strategies for combination therapeutic approaches

Obviousness Reasoning

Logical progression of existing therapeutic concepts using standard pharmaceutical research methodologies

Source Patent Element

CK2 inhibitor compound design targeting cancer and inflammatory processes

PTD Variation

Technical system implementing enhanced component interactions and mechanism refinements

Obviousness Reasoning

Systematic extension of existing technological framework using predictable engineering principles

Source Patent Element

Molecular structure with potential substituent variations

PTD Variation

Alternative embodiment configurations maintaining core structural principles

Obviousness Reasoning

Design choice demonstrating standard chemical engineering approach to technological variation

35 U.S.C. § 103 Summary: Based on comprehensive analysis of US Patent 11858934, the present technical disclosure constitutes prior art rendering obvious subsequent patent claims involving synergistic combination strategies for CK2 inhibitor compounds. A person having ordinary skill in the art would recognize the disclosed variations as predictable extensions of existing pharmaceutical research methodologies, thus satisfying obviousness criteria under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,858,934
Title	Substituted pyrido[4′,3′:5,6]pyrimido[1,2-a]indoles as CK2 inhibitors
Assignee(s)	KING FAISAL UNIVERSITY